“Strong Government Support, increasing healthcare expenditure, Patent expiries etc will drive the domestic pharma market to become US$ 53 Billion by 2018”, says RNCOS.
Noida, UP -- (SBWIRE) -- 01/08/2015 -- According to a new research report by RNCOS entitled, "Brazil Pharmaceutical Market Outlook 2018", Brazil has potential to become the third largest pharma markets after the US and China. Government's support to encourage domestic generics industry, patent expiries, increasing healthcare expenditure of public and private insurance sector, rising disposable income, rising ageing population etc., have been the major growth drivers. Brazil is the only Country in emerging world to have a subsequent increase in the healthcare expenditure which is one of the key growth factors in the healthcare sector. Also, it is one of the few countries that provides free medicines to people under lower income groups and patients with chronic diseases.
Following Government Support and increasing research and development, the domestic pharmaceutical industry witnessed a stupendous growth last year. The market, which stood at around US$ 27 Billion in 2013 has the potential to double in the next five years. Over-the-Counter drug and Generic drug segments have been the fastest growing segments and are expected to surpass the branded medications market in the near future. EMS Pharma, Hypermarcas, Ache Laboratories, Eurofarma are the top four domestic pharma companies, with EMS Pharma and Ache Laboratories leading the Generics and Prescription Drug segments respectively.
Research Analysis and Highlights
The report is spread in over 85 pages and provides an in-depth research and rational analysis of the current status and future prospect of the Brazilian Pharmaceutical industry. The study presents a transparent picture about different pharma segments such as Generics, OTC and Prescription Drugs including the factors affecting their growth. The research further covers Pharmaceutical Production, Therapeutic Segments, Growth Drivers and Challenges as well as Mergers and Acquisitions. The report also covers detailed information about active market players in the Brazil pharmaceutical industry, including domestic and foreign players to enable the clients to understand the market structure and its growth during the forecasted period. In brief, the report covers all the necessary aspects of the Brazilian Pharmaceutical market, providing an in-depth research and prudent analysis of the key segments.
Some of the report's key highlights include:
- Growth Drivers such as Increasing private and public health expenditure, Rising Disposable Income, Growing Ageing Population and Rising number of Clinical Trials.
- Market Segmentation by Pharma ingredients, Drugs segments and Drug usage.
- Mergers and Acquisitions, including premium deals since 2010.
- Leading Players and their share in Brazilian Pharma market.
For FREE SAMPLE of this report visit: http://www.rncos.com/Report/IM726.htm
Check Related REPORTS on: http://www.rncos.com/Healthcare_Industry.htm
RNCOS is a leading industry research and consultancy firm incorporated in 2002. As a pioneer in syndicate market research, our vision is to be a global leader in the industry research space by providing research reports and actionable insights to companies across a range of industries such as Healthcare, IT and Telecom and Retail etc. We offer comprehensive industry research studies, bespoke research and consultancy services to Fortune 1000, Trade associations, and Government agencies worldwide.